As of Sep 28
| -0.31 / -4.70%|
The 7 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 7.00, with a high estimate of 13.00 and a low estimate of 6.00. The median estimate represents a +11.46% increase from the last price of 6.28.
The current consensus among 8 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.